Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Are there any special considerations when giving breast radiation to a patient with Sjogren's syndrome?
Do you adjust dose/fractionation?
Answer from: Radiation Oncologist at Community Practice
I have not adjusted my dose/fractionation or approach for patients with Sjogrens. I have also offered both WBI and PBI.
Sign in or Register to read more
8438
Related Questions
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Is Behcet's disease a contraindication to breast conserving therapy?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
When treating APBI with the Florence regimen, are you using daily or every other day fractionation?
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
For a young female (<40) with HR-/HER2+ cT1-2N1, ypT1aN0 s/p mastectomy with SLNB, would you offer PMRT?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?